Zydus Lifesciences gets USFDA nod for Deflazacort oral suspension
Zydus Lifesciences Ltd on Monday said it has received final approval from the US health regulator for its generic version of Deflazacort oral suspension used in treating a severe form of inherited muscular dystrophy. The approval by the US Food and Drug Administration (USFDA) is for Deflazacort oral suspension of strength 22.75 mg/ml, Zydus Lifesciences…